131I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: the first case report in Thailand.
Radioimmunotherapy (RIT) with 131-rituximab is a safe and effective treatment in patients with relapsed, refractory follicular lymphoma. The authors demonstrated the first case of 131-rituximab treatment in the patient with relapsed non-Hodgkin's lymphoma (NHL) in Thailand. There was no immediate complication after treatment. Impressive treatment response occurred.
Division of Nuclear Medicine, Department of Radiology, Faculty ofMedicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. arpakorn13521@gmail.com
Arpakorn
A
Kositwattanarerk
Wirote
W
Changmuang
Jatupol
J
Sangsuriyan
Kittiphong
K
Thongklam
Chanika
C
Sritara
Chirawat
C
Utamakul
Wichana
W
Chamroonrat
Kanungnij
K
Thamnirat
Yoch
Y
Anongpornyochkul
Suporn
S
Chancharunee
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D012008:Recurrence; D000069283:Rituximab; D013785:Thailand
D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; C507388:131I-rituximab